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Background: Patients with schizoaffective disorder (SAD) suffer from cognitive
impairment, which negatively influences their functionality. Cognitive remediation (CR)
interventions have been shown to be effective in patients with schizophrenia (SZ) and
bipolar disorder (BD), but evidence in SAD is limited so far. The aim of this study is to
systematically review the published data on CR interventions, either in neurocognition or
social cognition, in patients with SAD.
Methods: We conducted a comprehensive, computerized literature search using terms
related to CR interventions in psychotic and affective disorders, and particularly in
SAD. Pubmed, Embase, and Web of Knowledge databases were used up to February
28th, 2018 according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement. The search returned 2672 articles of which four
were finally selected meeting the inclusion criteria.
Results: Cognitive Enhancement Therapy, computerized Cognitive Remediation
Therapy and Cognitive Training showed positive results in subsamples of patients with
SAD regarding neurocognition and functioning in comparable terms to patients with
schizophrenia as well as in a greater extent in quality of life. Benefits in social cognition
were also described when Social Cognition Interaction Training was considered in
patients with SAD.
Conclusions: CR interventions seem to improve neurocognition and social cognition in
patients with SAD as well as functioning and quality of life. However, further randomized
controlled trials on CR interventions with an optimized design focusing on selected
sample of patients with SAD are imperative.
Keywords: schizoaffective disorder, affective psychosis, cognitive enhancement, cognitive remediation, cognitive
rehabilitation, cognitive training
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INTRODUCTION
Cognitive impairment is highly prevalent in several mental
disorders, especially in those presenting with psychotic
symptoms (1–5). Therefore, a neuropsychological examination
of patients with psychiatric disorders has been progressively
integrated in the elementary assessment of these patients (6, 7).
Cognitive impairment has been widely studied in patients
with schizophrenia (SZ), who usually exhibit some cognitive
dysfunction preceding the illness onset (8). The most prevalent
impaired cognitive domains in these patients are attention,
processing speed, working memory, and problem solving (9–11).
Cognitive impairment is also common in bipolar disorder
(BD) even during euthymia (12–15). Although a subgroup of
patients with BD may present some mild cognitive deficits
before illness onset or even a higher cognitive performance
than healthy population, most patients present an average
cognitive performance until the first episode (16–18). After
illness onset, cognitive performance in BD declines in particular
in the domains of attention, verbal learning and memory, and
executive functions according to clinical severity and number of
relapses (8, 13, 19). Therefore, in general terms, there are many
similarities between SZ and BD including scope of cognitive
domains (20, 21).
First descriptions on cognitive performance of patients with
schizoaffective disorder (SAD) come from studies with mixed
samples of patient with SAD and SZ (22–24). Later, comparisons
on the cognitive performance between SAD and SZ were also
published (25–33). On the one hand, studies suggested that
both groups of patients might present a similar pattern of
neurocognitive impairment, especially in memory, executive
functions, cognitive flexibility, reasoning, and problem solving
(25–28). On the other hand, subsequent studies described
less severity of neurocognitive impairment in patients with
SAD compared to patients with SZ (29–33). Concerning social
cognition, patients with SAD displayed a higher performance on
tasks related to the Theory of Mind (ToM) compared to patients
with SZ (32). When comparing the neurocognitive performance
between patients with SAD and BD, poorer execution in verbal
memory and occupational functioning has been detected in
patients with SAD (4). All in all, these findings evidence the
cognitive heterogeneity in patients with SAD (31, 34) and place
this disorder in an intermediate position in terms of cognitive
performance between SZ and BD although possibly closer to SZ
(35). In terms of structural neuroimaging abnormalities, SAD
also resembles more SZ than BD (36).
Since cognitive impairment is related to a worse clinical
course and poor functional outcome (3, 37–40), it needs to be
considered as a therapeutic clinical target in order to improve
both psychosocial functioning and quality of life of patients
with SAD (41–44). Nowadays some studies have suggested that
social cognition may explain more functional outcome variance
than neurocognition and that is why social cognition has been
increasingly considered as another important treatment target
(45, 46). Cognitive remediation (CR) interventions in psychiatric
disorders are psychological or pharmacological based approaches
(42). Concerning pharmacological treatments in affective and
psychotic disorders, evidence so far suggests only a small effect
on cognitive improvement; several drugs with potential pro-
cognitive effects are currently being investigated (47, 48). With
regards to psychological approaches, CR interventions have been
developed to improve cognitive processes such as attention,
memory, executive function, social cognition, and metacognition
(Cognitive Remediation ExpertsWorkshop, April, 2010) (49, 50).
The evidence of CR in neurocognition and social cognition
in patients with SAD mainly stems from mixed sample studies,
generally of patients with SAD and SZ or in fewer cases patients
with SAD and BD (51). Although there are no studies focused
exclusively on analyzing the efficacy of cognitive interventions
in samples composed by patients with SAD, a systematic
review about cognitive rehabilitation on patients with SAD
as well as affective disorders hinted an improvement on the
level of cognitive performance after completion of cognitive
remediation in patients with SAD (52). The data of SAD in
this study were determined by estimated pooled effect size (ES)
weighted for the percentage of patients with SAD. Potential
changes in other outcomes apart from cognition, such as
social cognition, psychosocial functioning, and quality of life
were not analyzed. According to the lack of knowledge of CR
interventions in patients with SAD, we aimed to systematically
review the evidence on CR interventions in neurocognition,
social cognition, psychosocial functioning, and quality of life in
patient with SAD exclusively and describe their possible benefits
in these particular patients.
METHODS
This systematic review was conducted following the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) guidelines (53).
Data Sources and Search Terms
A comprehensive literature search of CR interventions in SAD
was conducted by three authors independently (EL, BS, and IG)
using the search terms in Pubmed, Embase, and Web of Science
electronic databases from inception to February 28th, 2018.
The following Boolean logic algorithms were used: In
Pubmed, (schizoaffective OR schizo-affective OR “affective
disorder” OR “affective psychosis” OR “bipolar” OR “manic
depression” OR schizophrenia OR “schizophreniform
psychosis”) AND (“cognition training” OR “cognition
therapy” OR “cognitive remediation” OR “cognitive training”
OR “cognitive rehabilitation” OR “cognitive therapy”
OR “cognitive intervention” OR “cognitive treatment” OR
“neurocognitive remediation” OR “neurocognitive training” OR
“neurocognitive rehabilitation” OR “neurocognitive therapy” OR
“neurocognitive intervention” OR “neurocognitive treatment”
OR “neuropsychological training” OR “neuropsychological
rehabilitation” OR “neuropsychological therapy” OR
“neuropsychological treatment” OR “metacognitive training”);
and in Embase and Web of Science: “schizoaffective AND
(“cognitive remediation” OR “cognitive rehabilitation” OR
“cognitive training”).
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Reference list of individual papers were also examined to
identify any additional relevant studies.
Study Inclusion Criteria
Records were reviewed using the following inclusion
criteria: (1) Published studies (randomized clinical trials
and follow-up cohort studies) about cognitive interventions
targeted at improving cognitive skills, functioning, or
quality of life which reported results about the sample or
subsample of patients with SAD with at least 2 timing
outcomes measures; (2) number or proportion of cases
diagnosed with SAD in the sample; (3) diagnoses of SAD
according to DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR,
DSM-5, ICD-9, or ICD-10; (4) no language restrictions
were applied in this review; (5) no comparator group was
imperative.
FIGURE 1 | PRISMA flow-chart of the studies considered and finally selected for review.
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Study Exclusion Criteria
The exclusion criteria applied were: (1) meta-analyses, systematic
or narrative reviews, single cases, cases series, study protocols,
letters to the editor, editorials, debate articles, opinion papers
or congress abstracts; (2) interventions not involving CR
interventions; (3) trials without identifying the number of
participants with SAD; (4) studies without concrete outcomes
about patients with SAD.
Procedures and Data Extraction
Articles were selected based on title and abstract and, when
necessary, on examination of the full text to assess its relevance.
After elimination of duplicated sources, the full texts of the
potentially eligible studies were considered. References were also
reviewed to identify further possible studies of interest. Most
existing articles on this subject about patients with psychosis and
BDwere reviewed, since in many cases the sample was mixed and
the diagnosis of SAD was not detected in the search.
Extracted information was synthesized in two tables. In
Table 1 the characteristics of the selected studies andmain results
are summarized: (a) first author and year of publication; (b)
characteristics of the sample: (c) sample diagnosis; (d) study
design; (e) outcome measures; (f) results summary; and (g)
limitations. In Table 2 the characteristics of the interventions
applied according to the following structure: (a) intervention; (b)
target; (c) duration; (d) setting: individual or group intervention;
and (e) type: computer assisted or non-computer assisted
sessions.
RESULTS
Using the aforementioned keywords, the search returned
2672 records (Figure 1). The literature search identified 554
potentially relevant studies. After excluding studies that did not
include or describe the sample of patients with SAD and their
outcomes, four papers were identified according to the inclusion
criteria (54–57).
The sample consisted of 73 patients with SAD out of 216
(Table 1).Two studies were performed in USA (55, 57), one in
Germany (56), and one in Spain (54). The average study global
sample size was 54 (SD 22.4) participants ranging from 32 to
89 patients. 58.3% of participants were men with a mean age of
38.1 (SD = 9.2) years. Three studies reported participants illness
duration (54, 55, 57) which ranged from 3.2 to 30 years with a
mean duration of 16.6 (SD 13.9) years. The average percentage
of patients with SAD in the four studies was 33.8% in a range
from 10.8 to 44%. The study with the largest sample of SAD was
carried by Twamley et al. (57) with a sample of 39 patients. The
interventions carried out in each study are described in Table 2.
Lewandowski et al. (55) compared a group that received
Cognitive Enhancement Therapy (CET) with another group that
received Enriched Supportive Therapy (EST) as a control group
in a randomized controlled trial. The total sample included 20
patients with SAD and 38 with SZ. The authors conducted a
secondary analysis comparing cognitive outcomes in patients
with SAD and SZ with positive findings for CET in both
diagnoses. The authors did not find a significant influence
of the diagnosis on the relationship between improvement
and treatment condition for the domains of processing
speed, neurocognition, cognitive style, social cognition, social
adjustment, or symptoms. Moreover, they described significant
benefits for CET vs. EST for both SAD and SZ in within-
group analysis: social cognition (SAD d = 1.69, SZ d = 1.68);
social adjustment (SAD d = 1.36, SZ d = 1.65); and symptoms
(SAD d = 1.00, SZ d = 0.68); all p < 0.045. In patients
with SZ, CET produced significant improvement over EST
in neurocognition (d = 0.46, p = 0.025) and cognitive style
(d = 1.08, p = 0.009), however only trend-level effects were
observed among patients with SAD (d = 0.52, p = 0.089 and
d = 0.99, p = 0.098, respectively). No significant effect of the
diagnosis on clinical improvement was found, with the exception
of a significant reduction on depressive and anxious symptoms
in patients with SAD (p = 0.019). This may be due to higher
levels of anxiety and depression at baseline in this group of
patients.
The computerized Cognitive Remediation Therapy (cCRT) is
the intervention used in the study by Scheu et al. This study
sample included 10 patients with SAD and 22 with SZ. After 4
weeks, the authors observed a significant improvement in the
neurocognitive performance that involved attention memory,
strategy, numeracy and visuo-motor skills in patients with
SAD and SZ (56). No significant differences were found in
improvement rates between both diagnostic groups. There was
no significant correlation between improvement rates and the
number of attended training sessions, but better improvement
rates were linked to a higher total number of completed tasks
(r = 0.36, p < 0.05). Correlation analyses revealed no significant
relationship between any of the baseline cognitive or symptom
measures and improvement rates. Cognitive improvements on
processing speed and verbal memory were associated with
higher baseline scores on the general PANSS and total PANSS
(r = −0.44, p < 0.05; r = −0.45, p < 0.01, respectively),
while improvements on Trail Making Test A were related to
higher scores in the positive PANSS (r = −0.43, p < 0.05).
Higher scores in the PANSS scores indicated worse clinical
state.
Twamley et al. (57) studied the efficacy of Cognitive Training
(CT) and Standard Pharmacotherapy (SP) compared to SP alone
in a mixed sample of 39 patients with SAD, 45 with SZ and
5 with psychosis not otherwise specified. Patients showed a
significant improvement in attention (p= 0.049), verbal memory
(p = 0.017), and negative symptoms severity (p = 0.002)
at 3-month follow-up and in verbal memory (p = 0.039),
prospective memory (p= 0.050), functional capacity (p= 0.004),
negative symptoms severity (p = 0.025), and self-reported
quality of life (p = 0.004) at 6-month follow-up. Results of
cognitive outcomes were not available according to diagnoses.
However, patients with SAD showed a significant improvement
in subjective perception of quality of life at 6 months compared
to patients with SZ (p = 0.03) (57). At 3-month follow-up,
improvement in digit span forward and in Hopkins Verbal
Learning Test (HVLT) were associated with higher levels of
negative symptoms severity at baseline (r = 0.45, p = 0.045;
r = 0.50, p = 0.025, respectively). Moreover, improvement in
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TABLE 2 | Description of the studied Cognitive Remediation interventions in schizoaffective disorder.
Intervention Target Duration Setting Type
Cognitive
Enhancement Therapy
(CET)
Cognitive functions and
social cognition
Biweekly sessions (60 h cognitive
training + 45 h social cognition)
for 24 months
Individual/group Computer assisted and
non-computer assisted
sessions
computerized Cognitive
Remediation Therapy
cCRT (CogPack)
Cognitive function 50min sessions twice a week
over a maximum period of 8
weeks
Individual Computer assisted
Cognitive Training (CT) Cognitive function 2 h once a week for 12 weeks Group Non-computer assisted
Social Cognition and
Interaction Training
(SCIT)
Social cognition 1 h once a week for 18 weeks Group Non-computer assisted
digit span was related to higher levels of self-reported cognitive
problems (r = 0.48, p = 0.033). An improvement in HVLT
percent retention at 3 months was also associated with lower
cognitive strategy use at baseline (r = −0.48, p = 0.033).
At 6-month follow-up, improvement on the University of
California, San Diego, Performance-Based Skills Assessment
(UPSA) functional capacity was associated with higher levels
of positive symptoms (r = 0.45, p = 0.035), lower levels of
cognitive strategy use (r = −0.54, p = 0.009), and worse UPSA
performance at baseline (r =−0.56, p= 0.007).
Lahera et al. (54) described the benefits of Social Cognition
and Interaction Training (SCIT) compared to Treatment As
Usual (TAU) in a mixed sample of 4 patients with SAD and
33 with BD. The authors detected a significant improvement in
the group that received SCIT on each social cognitive outcome
except for the Ambiguous Intentions Hostility Questionnaire
(AIHQ) Intentionality subscale, with a trend to significance
(p = 0.069). The group that received SCIT showed a significant
improvement in emotion perception and ToM (p < 0.05), and
significant improvement in hostile attribution biases compared
to the TAU group (p < 0.05). The SCIT group showed a within-
group improvement on the AIHQ Blame subscale (d = −0.19, p
< 0.01), an improvement in AIHQHostility Bias (d=−0.55, p<
0.05), an improvement in scores on the Hinting Task (d = 0.4, p
< 0.05), an improvement on the Emotion Recognition-40 (ER40)
(d = 0.51, p < 0.05), and an improvement on the Face Emotion
Discrimination Task (FEDT) (d = 0.67, p < 0.01) and Face
Emotion Identification Task (FEIT) (d = 0.81, p < 0.05). Post-
hoc analysis did not evidence an effect of diagnoses on the results.
No evidence for between-group effects on any clinical outcome
was found.
The risk of bias was assessed in all eligible studies as
recommended by the Cochrane Collaboration (58). However
it was difficult to determine due to the heterogeneity of the
study design and because the focus of this systematic review was
beyond the main objectives of the selected articles.
DISCUSSION
Despite the scarce number of studies on the topic, there
is evidence, although limited, of the effectiveness of CR
interventions in patients with SAD. CET, cCRT, and CT showed
positive results in cognition in the subsample of patients with
SAD considering neurocognitive or functional parameters as well
as outcomes related to quality of life. Benefits in social cognition
were also described when SCIT as well as CET were considered
in patients with SAD.
These results are in line with previous bibliography on the
issue. Regarding neurocognition, Anaya et al. (52) described
in their meta-analysis that CR interventions showed positive
effects on cognition at post-intervention in patients with SAD
as well as in patients with affective disorders with an ES of
0.32. Interestingly, the authors pointed out that the effect of CR
interventions increased when the meta-analysis was limited to
studies that included exclusively patients with SAD, obtaining
a pooled ES weighted for the percentage of patients with SAD
of 0.41. In addition, we also have found some evidence that
schizoaffective patients could improve in specific measures of
social cognition, social adjustment, symptoms and quality of life
after receiving a CR intervention.
It is worth commenting on the studies that presented
a relevant percentage of patients with SAD in the sample
but did not specifically mention results of the subsample of
patients with SAD. Considering neurocognition, In a subsequent
article (59) of the one included in this systematic revision,
Twamley et al. described general improvement in cognitive
domains considering the entire sample. In another study with
53% of the sample diagnosed with SAD (60), computer-
assisted cognitive rehabilitation showed greater improvement
in neurocognitive performance, specifically in verbal memory
and attention, and negative symptoms compared to a wait-list
control group. Regarding social cognition, a recent systematic
review that included studies with samples of patients with SAD
and SZ (61) stated that interventions in social cognition could
improve several domains related to affect recognition, ToM
and social perception. However, the effect on attributional style
and the relationship between improvement in social cognition
and functioning were unclear. All in all, CR interventions in
neurocognition and social cognition seem to be effective in the
psychotic spectrum.
Whether patients diagnosed with SAD benefit from CR
interventions more than SZ or less than BD is still open to
question. Lewandowski et al. published the results of CET
between patients with SAD and SZ in a subanalysis of a previous
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study (55, 62). Although positive results were described in both
groups, a lower benefit of the treatment was observed in the
cognitive performance of patients with SAD compared to those
with SZ. This may be due to a ceiling effect since patients
diagnosed with SZ present more cognitive impairment compared
to patients diagnosed with SAD. The evidence suggests that the
wider the cognitive impairment at baseline, the greater benefits
can be obtained with CR interventions. It may be due to the
fact that there is more room for improvement or because of an
increased motivation (57). Nevertheless, in the study performed
by Scheu et al. (56), outcomes of patients with SAD did not
differ from those observed in patient with SZ, being positive in
both disorders. Thus, despite the cognitive heterogeneity (31,
34), SAD may be placed in an intermediate position in terms
of neurocognitive performance between SZ and BD although
possibly closer to SZ (35).
There is controversy about how basal clinical state may impact
on the results of CR and how CR may influence the clinical
state. With regard to the former, on one hand, Wykes et al.
(63) reported in a meta-analysis focused on CR in patients with
SZ that the benefits were more significant in less symptomatic
patients. On the other hand, Twamley et al. (57) found an
association between higher levels of negative symptoms and
greater benefits, and between higher levels of positive symptoms
and greater improvement in functional capacity. Therefore, they
consider that the presence or severity of symptoms should not
be an exclusion criterion for these interventions. Other authors
consider that the severity of positive or negative symptoms does
not predict the rate of improvement (19, 56, 64). Considering
the latter, the two meta-analyses by Wykes et al. and McGurk et
al. (63, 65) described a significant positive effect of CR on both
symptoms and functionality in patients with SZ. Lewandowski
et al. (55) detected greater improvement in symptoms after
receiving CET in patients diagnosed with SAD compared to
patients diagnosed with SZ, specifically in anxious and depressive
symptoms.
Another issue of debate is the right moment to provide
CR interventions. Some authors suggest that the younger the
patients, the more they benefit from CR interventions (63, 66–
68, 70). On the contrary, the two major meta-analysis in the
literature about CR interventions concluded no relationship
between these two variables or that the older the patients, the
better outcomes of CR interventions (63, 65). Twamley et al.
pointed out that older patients achieved more improvement,
specifically in prospective memory (57). The concept of cognitive
reserve may provide an explanation for the discrepancy in these
results since it reflects the capacity of the brain to endure
neuropathology and successfully complete cognitive tasks (69).
Moreover, cognitive reserve has been found as a significant
predictor of cognitive and psychosocial functioning in patients
with SZ and BD (70–72). Another key issue in CR interventions
relates to the relationship between number of sessions and the
obtained benefits. The meta-analysis carried out by Wykes et
al. (63) and the study of Scheu et al. (56) did not reveal any
association between the aforementioned variables. Last but not
least, the drop-out ratio is another matter of concern in CR
interventions. Twamley et al. (57) analyzed who was more likely
to drop out in their randomized controlled trial of CT in which
57.30% of the patients completed the therapy while 31.46% did
not start it and 11.24% withdrew. Those who completed CT had
more formal education and lower antipsychotic doses than had
dropouts with no CT exposure, but the groups did no otherwise
differ. In Lewandowski et al. (55) and Lahera et al. (54) studies,
the frequencies of dropouts were 20.6 and 19.1%, respectively.
As a summary, Lewandowski et al. (55) obtained small effects
on neurocognition in the group of SAD, vs. medium effects in
the group of SZ. However, patients with SAD improved more in
symptomatology after cognitive treatment. In this study, a similar
improvement in the functionality of both groups was obtained.
On the other hand, Scheu et al. (56) did not find differences in
improvement rates when comparing patients with SAD and SZ.
Lahera et al. (54) did not find differences after treatment when
compared patients with SAD and BD, considering that the sample
included four patients with SAD. Twamley et al. (57) did not
report group differences but more improvement in subjective
quality of life at 6 months in SAD compared to patient with SZ.
Despite data gathered in this systematic review seems to
support a positive effects of CR interventions in SAD, these
results should be interpreted with caution. First of all, the
samples of the four reviewed studies are restricted to small
subsamples of patients diagnosed with SAD within a wider
sample of patients diagnosed mostly with SZ or BD. Although
we only consider articles that studied the concrete subsample of
SAD, the obtained results stem from post-hoc analyses, which
are not always aligned with the aim of the primary objective
of the study and therefore may increase false positive results.
Moreover, the heterogeneity of the design of the reviewed CR
interventions should be beared in mind. This heterogeneity
could partly explain discrepancies among results from these
studies.
In this systematic review, scarce studies on CR interventions
in SAD were found. However, available data support that CR
interventions may improve neurocognition and social cognition
in this group of patients. Subsequently, functioning and quality
of life on this population may also benefit from improving the
daily life of patients with SAD. So as to confirm this hypothesis,
further randomized controlled trials on CR interventions with an
optimized design and selected sample of patients with SAD are
urged.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
ACKNOWLEDGMENTS
CMB would like to thank the Departament de Salut de la
Generalitat de Catalunya for the PERIS grant (SLT002/16/00331).
IG is supported by the Instituto de Salud Carlos III, Ministry
of Economy and Competitiveness of Spain [Juan Rodés Contract
(JR15/00012) and a grant (PI16/00187)] integrated into the
Plan Nacional de I+D+I and cofunded by ISCIII-Subdirección
Frontiers in Psychiatry | www.frontiersin.org 8 October 2018 | Volume 9 | Article 470
Lopez-Fernandez et al. Cognitive Remediation in Schizoaffective Disorder
General de Evaluación and Fondo Europeo de Desarrollo
Regional (FEDER).
EV thanks the support of the Spanish Ministry of Economy
and Competitiveness (PI15/00283) integrated into the Plan
Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección
General de Evaluación y el Fondo Europeo de Desarrollo
Regional (FEDER); CIBERSAM; and the Comissionat per a
Universitats i Recerca del DIUE de la Generalitat de Catalunya
to the Bipolar Disorders Group (2017 SGR 1365) and the
project SLT006/17/00357, from PERIS 2016-2020 (Departament
de Salut). CERCA Programme/Generalitat de Catalunya.
AM-A thanks the support of the Spanish Ministry of
Economy and Competitiveness (PI15/00330) integrated into
the Plan Nacional de I+D+I y cofinanciado por el ISCIII-
Subdirección General de Evaluación y el Fondo Europeo de
Desarrollo Regional (FEDER); CIBERSAM) and the project
SLT006/17/00177, from PERIS 2016-2020 (Departament de
Salut). CERCA Programme/Generalitat de Catalunya.
REFERENCES
1. Albus M, Hubmann W, Wahlheim C, Sobizack N, Franz U, Mohr F.
Contrasts in neuropsychological test profile between patients with first-
episode schizophrenia and first-episode affective disorders. Acta Psychiatr
Scand. (1996) 94:87–93.
2. Zubieta JK, Huguelet P, O’Neil RL, Giordani BJ. Cognitive function
in euthymic bipolar I disorder. Psychiatry Res. (2001) 102:9–20.
doi: 10.1016/S0165-1781(01)00242-6
3. Martínez-Arán A, Vieta E, Colom F, Torrent C, Sánchez-Moreno J, Reinares
M, et al. Cognitive impairment in euthymic bipolar patients: implications
for clinical and functional outcome. Bipolar Disord. (2004) 6:224–32.
doi: 10.1111/j.1399-5618.2004.00111.x
4. Torrent C, Martínez-Arán A, Amann B, Daban C, Tabarés-Seisdedos
R, González-Pinto A, et al. Cognitive impairment in schizoaffective
disorder: a comparison with non-psychotic bipolar and healthy subjects.
Acta Psychiatr Scand. (2007) 116:453–60. doi: 10.1111/j.1600-0447.2007.
01072.x
5. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, et al.
Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders
depends on history of psychosis rather than diagnostic group. Schizophr Bull.
(2011) 37:73–83. doi: 10.1093/schbul/sbp034
6. Miskowiak K, Burdick K, Martinez-Aran A, Bonnin CM, Bowie CR,
Carvalho AF, et al. Methodological recommendations for cognition trials
in bipolar disorder by the International Society for Bipolar Disorders
Targeting Cognition Task Force. Bipolar Disord. (2017) 19:614–26.
doi: 10.1111/bdi.12534
7. Miskowiak K, Burdick K, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho
AF, et al. Assessing and addressing cognitive impairment in bipolar disorder:
the International Society for Bipolar Disorders Targeting Cognition Task
Force recommendations for clinicians. Bipolar Disord. (2018) 20:184–94.
doi: 10.1111/bdi.12595
8. Lewandowski KE, Cohen BM, Öngur D. Evolution of neuropsychological
dysfunction during the course of schizophrenia and bipolar disorder. Psychol
Med. (2011) 41:225–41. doi: 10.1017/S0033291710001042
9. Dickinson D, Ramsey ME, Gold JM. Overlooking the Obvious: a
meta-analytic comparison of digit symbol coding tasks and other
cognitive measures in schizophrenia. Arch Gen Psychiatry (2007) 64:532.
doi: 10.1001/archpsyc.64.5.532
10. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia:
a quantitative review of the evidence. Neuropsychology (1998)
12:426–45.
11. Palmer BW, Dawes SE, Heaton RK. What Do we know about
neuropsychological aspects of schizophrenia? Neuropsychol Rev. (2009)
19:365–84. doi: 10.1007/s11065-009-9109-y
12. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier
IN, et al. A meta-analysis of cognitive deficits in euthymic patients with
bipolar disorder. J Affect Disord. (2006) 93:105–15. doi: 10.1016/j.jad.2006.
02.016
13. Bourne C, Aydemir O, Balanzá-Martínez V, Bora E, Brissos S,
Cavanagh JT, et al. Neuropsychological testing of cognitive impairment
in euthymic bipolar disorder: an individual patient data meta-
analysis. Acta Psychiatr Scand. (2013) 128:149–62. doi: 10.1111/acps.
12133
14. Bortolato B, Miskowiak K, Köhler CA, Vieta E, Carvalho AF. Cognitive
dysfunction in bipolar disorder and schizophrenia: a systematic
review of meta-analyses. Neuropsychiatr Dis Treat. (2015) 11:3111–25.
doi: 10.2147/NDT.S76700
15. Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of
neuropsychological functioning in euthymic bipolar disorder: an update
and investigation of moderator variables. Bipolar Disord. (2011) 13:334–42.
doi: 10.1111/j.1399-5618.2011.00935.x
16. Martino DJ, Samamé C, Ibañez A, Strejilevich SA. Neurocognitive functioning
in the premorbid stage and in the first episode of bipolar disorder: a systematic
review. Psychiatry Res. (2015) 226:23–30. doi: 10.1016/j.psychres.2014.
12.044
17. Mollon J, David AS, Zammit S, Lewis G, Reichenberg A. Course of cognitive
development from infancy to early adulthood in the psychosis spectrum.
JAMA Psychiatry (2018) 75:270–9. doi: 10.1001/jamapsychiatry.2017.4327
18. Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, et
al. Bipolar disorders. Nat Rev Dis Prim. (2018) 4:18008. doi: 10.1038/nrdp.
2018.8
19. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive
deficits in bipolar illness: profile and effects of clinical state. Neuropsychology
(2009) 23:551–62. doi: 10.1037/a0016277
20. Bora E, Yücel M, Pantelis C. Cognitive impairment in affective psychoses: a
meta-analysis. Schizophr Bull. (2010) 36:112–25. doi: 10.1093/shbul/sbp093
21. Martínez-Arán A, Penadés R, Vieta E, Colom F, Reinares M,
Benabarre A, et al. Executive function in patients with remitted
bipolar disorder and schizophrenia and its relationship with functional
outcome. Psychother Psychosom. (2002) 71:39–46. doi: 10.1159/0000
49342
22. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health
longitudinal study of chronic schizophrenia. Prognosis and predictors of
outcome. Arch Gen Psychiatry (1991) 48:239–46.
23. Brekke JS, Raine A, Ansel M, Lencz T, Bird L. Neuropsychological and
psychophysiological correlates of psychosocial functioning in schizophrenia.
Schizophr Bull. (1997) 23:19–28.
24. Lysaker PH, Bryson GJ, Davis LW, Bell MD. Relationship of impaired
processing speed and flexibility of abstract thought to improvements in work
performance over time in schizophrenia. Schizophr Res. (2005) 75:211–8.
doi: 10.1016/j.schres.2004.09.014
25. Manschreck TC,Maher BA, Beaudette SM, RedmondDA. Context memory in
schizoaffective and schizophrenic disorders. Schizophr Res. (1997) 26:153–61.
26. Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV.
Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin
Psychiatry (1999) 60:874–82.
27. Gooding DC, Tallent KA. Spatial working memory performance in patients
with schizoaffective psychosis versus schizophrenia: a tale of two disorders?
Schizophr Res. (2002) 53:209–18. doi: 10.1016/S0920-9964(01)00258-4
28. Reichenberg A, Weiser M, Rabinowitz J, Caspi A, Schmeidler J,
Mark M, et al. A population-based cohort study of premorbid
intellectual, language, and behavioral functioning in patients with
schizophrenia, schizoaffective disorder, and nonpsychotic bipolar
disorder. Am J Psychiatry (2002) 159:2027–35. doi: 10.1176/appi.ajp.159.
12.2027
29. Gruber O, Gruber E, Falkai P. Articulatory rehearsal in verbal working
memory: a possible neurocognitive endophenotype that differentiates between
Frontiers in Psychiatry | www.frontiersin.org 9 October 2018 | Volume 9 | Article 470
Lopez-Fernandez et al. Cognitive Remediation in Schizoaffective Disorder
schizophrenia and schizoaffective disorder. Neurosci Lett. (2006) 405:24–8.
doi: 10.1016/j.neulet.2006.06.062
30. Heinrichs RW, Ammari N, McDermid Vaz S, Miles AA. Are
schizophrenia and schizoaffective disorder neuropsychologically
distinguishable? Schizophr Res. (2008) 99:149–54. doi: 10.1016/j.schres.2007.
10.007
31. Goldstein G, Shemansky WJ, Allen DN. Cognitive function in schizoaffective
disorder and clinical subtypes of schizophrenia. Arch Clin Neuropsychol.
(2005) 20:153–9. doi: 10.1016/j.acn.2004.03.008
32. Stip E, Sepehry AA, Prouteau A, Briand C, Nicole L, Lalonde P, et al. Cognitive
discernible factors between schizophrenia and schizoaffective disorder. Brain
Cogn. (2005) 59:292–5. doi: 10.1016/j.bandc.2005.07.003
33. Fiszdon JM, Richardson R, Greig T, Bell MD. A comparison of basic and social
cognition between schizophrenia and schizoaffective disorder. Schizophr Res.
(2007) 91:117–21. doi: 10.1016/j.schres.2006.12.012
34. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia,
schizoaffective disorder and affective psychoses: meta-analytic study. Br
J Psychiatry J Ment Sci. (2009) 195:475–82. doi: 10.1192/bjp.bp.108.
055731
35. Madre M, Canales-Rodríguez EJ, Ortiz-Gil J, Murru A, Torrent C, Bramon E,
et al. Neuropsychological and neuroimaging underpinnings of schizoaffective
disorder: a systematic review. Acta Psychiatr Scand. (2016) 134:16–30.
doi: 10.1111/acps.12564
36. Amann BL, Canales-Rodríguez EJ, Madre M, Radua J, Monte G, Alonso-
Lana S, et al. Brain structural changes in schizoaffective disorder compared to
schizophrenia and bipolar disorder. Acta Psychiatr Scand. (2016) 133:23–33.
doi: 10.1111/acps.12440
37. Medalia A, Richardson R. What predicts a good response to
cognitive remediation interventions? Schizophr Bull. (2005) 31:942–53.
doi: 10.1093/schbul/sbi045
38. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional
outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull.
(2000) 26:119–36. doi: 10.1093/oxfordjournals.schbul.a033430
39. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and
functional outcome in schizophrenia: implications for MATRICS. Schizophr
Res. (2004) 72:41–51. doi: 10.1016/j.schres.2004.09.009
40. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M,
et al. Efficacy and specificity of Social Cognitive Skills Training for
outpatients with psychotic disorders. J Psychiatr Res. (2011) 45:1113–22.
doi: 10.1016/j.jpsychires.2011.01.015
41. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet (2016)
387:1561–72. doi: 10.1016/S0140-6736(15)00241-X
42. Solé B, Jiménez E, Torrent C, Reinares M, Bonnin CDM, Torres
I, et al. Cognitive impairment in bipolar disorder: treatment and
prevention strategies. Int J Neuropsychopharmacol. (2017) 20:670–80.
doi: 10.1093/ijnp/pyx032
43. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of
the cognitive and negative symptoms in schizophrenia. CNS Spectr. (2014)
19(Suppl. 1):38–52, 53. doi:10.1017/S1092852914000601.
44. Bonnín CM, Yatham LN, Michalak EE, Martínez-Arán A, Dhanoa
T, Torres I, et al. Psychometric properties of the well-being index
(WHO-5) spanish version in a sample of euthymic patients with
bipolar disorder. J Affect Disord. (2018) 228:153–9. doi: 10.1016/j.jad.2017.
12.006
45. Fett A-KJ, Viechtbauer W, Dominguez M-G, Penn DL, van Os J, Krabbendam
L. The relationship between neurocognition and social cognition with
functional outcomes in schizophrenia: ameta-analysis.Neurosci Biobehav Rev.
(2011) 35:573–88. doi: 10.1016/j.neubiorev.2010.07.001
46. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition
in schizophrenia: recommendations from the measurement and treatment
research to improve cognition in schizophrenia new approaches conference.
Schizophr Bull. (2005) 31:882–7. doi: 10.1093/schbul/sbi049
47. Salagre E, Solé B, Tomioka Y, Fernandes BS, Hidalgo-Mazzei D, Garriga
M, et al. Treatment of neurocognitive symptoms in unipolar depression: a
systematic review and future perspectives. J Affect Disord. (2017) 221:205–21.
doi: 10.1016/j.jad.2017.06.034
48. Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, et al.
Early intervention in bipolar disorder. Am J Psychiatry (2018) 175:411–26.
doi: 10.1176/appi.ajp.2017.17090972
49. Cella M, Reeder C, Wykes T. Group cognitive remediation for schizophrenia:
exploring the role of therapist support and metacognition. Psychol Psychother
Theor. (2016) 89:1–14. doi: 10.1111/papt.12062
50. Twamley EW, Jeste D V, Bellack AS. A review of cognitive
training in schizophrenia. Schizophr Bull. (2003) 29:359–82.
doi: 10.1093/oxfordjournals.schbul.a007011
51. Murru A, Pacchiarotti I, Nivoli AMA, Grande I, Colom F, Vieta E. What we
know and what we don’t know about the treatment of schizoaffective disorder.
Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. (2011) 21:680–
90. doi: 10.1016/j.euroneuro.2011.03.001
52. Anaya C, Martinez Aran A, Ayuso-Mateos JL, Wykes T, Vieta E, Scott
J. A systematic review of cognitive remediation for schizo-affective and
affective disorders. J Affect Disord. (2012) 142:13–21. doi: 10.1016/j.jad.2012.
04.020
53. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009)
339:b2535. doi: 10.1371/journal.pmed.1000097
54. Lahera G, Benito A, Montes JM, Fernández-Liria A, Olbert CM, Penn
DL. Social cognition and interaction training (SCIT) for outpatients with
bipolar disorder. J Affect Disord. (2013) 146:132–36. doi: 10.1016/j.jad.2012.
06.032
55. Lewandowski KE, Eack SM, Hogarty SS, Greenwald DP, Keshavan MS.
Is cognitive enhancement therapy equally effective for patients with
schizophrenia and schizoaffective disorder? Schizophr Res. (2011) 125:291–4.
doi: 10.1016/j.schres.2010.11.017
56. Scheu F, Aghotor J, Pfueller U, Moritz S, Bohn F, Weisbrod M,
et al. Predictors of performance improvements within a cognitive
remediation program for schizophrenia. Psychiatry Res. (2013) 209:375–80.
doi: 10.1016/j.psychres.2013.04.015
57. Twamley EW, Burton CZ, Vella L. Compensatory cognitive training for
psychosis: who benefits? who stays in treatment? Schizophr Bull. (2011)
37(Suppl. 2):S55–62. doi: 10.1093/schbul/sbr059
58. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.
The Cochrane Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ (2011) 343:d5928. doi: 10.1136/bmj.d5928
59. Twamley EW, Vella L, Burton CZ, Heaton RK, Jeste DV. Compensatory
cognitive training for psychosis. J Clin Psychiatry (2012) 73:1212–9.
doi: 10.4088/JCP.12m07686
60. Bellucci DM, Glaberman K, Haslam N. Computer-assisted cognitive
rehabilitation reduces negative symptoms in the severely mentally
ill. Schizophr Res. (2003) 59:225–32. doi: 10.1016/S0920-9964(01)
00402-9
61. Grant N, Lawrence M, Preti A, Wykes T, Cella M. Social cognition
interventions for people with schizophrenia: a systematic review
focussing on methodological quality and intervention modality.
Clin Psychol Rev. (2017) 56:55–64. doi: 10.1016/j.cpr.2017.
06.001
62. Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL,
Montrose DM, et al. Cognitive enhancement therapy for early-
course schizophrenia: effects of a two-year randomized controlled
trial. Psychiatr Serv. (2009) 60:1468–76. doi: 10.1176/ps.2009.60.
11.1468
63. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A Meta-
analysis of cognitive remediation for schizophrenia: methodology and
effect sizes. Am J Psychiatry (2011) 168:472–85. doi: 10.1176/appi.ajp.2010.
10060855
64. Fiszdon JM, Cardenas AS, Bryson GJ, Bell MD. Predictors of remediation
success on a trained memory task. J Nerv Ment Dis. (2005) 193:602–8.
doi: 10.1097/01.nmd.0000177790.23311.ba
65. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT.
A Meta-analysis of cognitive remediation in schizophrenia. Am
J Psychiatry (2007) 164:1791–802. doi: 10.1176/appi.ajp.2007.
07060906
Frontiers in Psychiatry | www.frontiersin.org 10 October 2018 | Volume 9 | Article 470
Lopez-Fernandez et al. Cognitive Remediation in Schizoaffective Disorder
66. Barlati S, Deste G, De Peri L, Ariu C, Vita A. Cognitive remediation in
schizophrenia: current status and future perspectives. Schizophr Res Treat.
(2013) 2013:156084. doi: 10.1155/2013/156084
67. Kurtz MM, Moberg PJ, Gur RC, Gur RE. Approaches to cognitive
remediation of neuropsychological deficits in schizophrenia: a review and
meta-analysis. Neuropsychol Rev. (2001) 11:197–210. doi: 10.1023/A:1012953
108158
68. Tomioka Y, Jiménez E, Salagre E, Arias B, Mitjans M, Ruiz V,
et al. Association between genetic variation in the myo-inositol
monophosphatase 2 (IMPA2) gene and age at onset of bipolar
disorder. J Affect Disord. (2018) 232:229–36. doi: 10.1016/j.jad.2018.
02.002
69. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease.
Lancet Neurol. (2012) 11:1006–12. doi: 10.1016/S1474-4422(12)
70191-6
70. Grande I, Sanchez-Moreno J, Sole B, Jimenez E, Torrent C, Bonnin CM, et al.
High cognitive reserve in bipolar disorders as a moderator of neurocognitive
impairment. J Affect Disord. (2017) 208:621–7. doi: 10.1016/j.jad.2016.
10.012
71. Anaya C, Torrent C, Caballero FF, Vieta E, Bonnin C del M, Ayuso-Mateos
JL. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial
functioning and quality of life. Acta Psychiatr Scand. (2016) 133:386–98.
doi: 10.1111/acps.12535
72. Amoretti S, Cabrera B, Torrent C, Mezquida G, Lobo A, González-Pinto A,
et al. Cognitive reserve as an outcome predictor: first-episode affective versus
non-affective psychosis.Acta Psychiatr Scand. (2018). doi: 10.1111/acps.12949.
[Epub ahead of print].
Conflict of Interest Statement: IG has served as a consultant for Ferrer,
advisor for Lundbeck, Otsuka and has been a speaker for Ferrer, Janssen and
Lundbeck, Otsuka. EV has received grants and served as a consultant, advisor,
or CME speaker for the following entities: AB-Biotics, Allergan, AstraZeneca,
Bristol-Myers-Squibb, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-
Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier,
Shire, Sunovion, Takeda, Telefonica, the Brain and Behaviour Foundation, the
Spanish Ministry of Science and Innovation (Centro de Investigación Biomédica
en Red de Salud Mental), the Seventh European Framework Programme
(European Network of Bipolar Research Expert Centres), and the Stanley Medical
Research Institute.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
The reviewer RS and handling editor declared their shared affiliation at time
of review.
Copyright © 2018 Lopez-Fernandez, Sole, Jimenez, Salagre, Gimenez, Murru,
Bonnín, Amann, Grande, Vieta and Martínez-Aran. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Psychiatry | www.frontiersin.org 11 October 2018 | Volume 9 | Article 470
